

Adithya Cattamanchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5531722/publications.pdf>

Version: 2024-02-01

99
papers

4,059
citations

201674

27
h-index

128289

60
g-index

110
all docs

110
docs citations

110
times ranked

5065
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 507-518.	9.1	28
2	Addressing health disparities through implementation science—a need to integrate an equity lens from the outset. <i>Implementation Science</i> , 2022, 17, 13.	6.9	51
3	Cost and Cost-Effectiveness of a Digital Adherence Technology for Tuberculosis Treatment Support in Uganda. <i>Value in Health</i> , 2022, 25, 924-930.	0.3	8
4	Readiness to implement on-site molecular testing for tuberculosis in community health centers in Uganda. <i>Implementation Science Communications</i> , 2022, 3, 9.	2.2	4
5	OUP accepted manuscript. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, , .	1.3	3
6	Perceptions, preferences, and experiences of tuberculosis education and counselling among patients and providers in Kampala, Uganda: A qualitative study. <i>Global Public Health</i> , 2022, 17, 2911-2928.	2.0	2
7	Implementing pediatric inpatient asthma pathways. <i>Journal of Asthma</i> , 2021, 58, 893-902.	1.7	4
8	A Prospective Evaluation of Xpert MTB/RIF Ultra for Childhood Pulmonary Tuberculosis in Uganda. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 586-592.	1.3	9
9	Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda. <i>PLoS ONE</i> , 2021, 16, e0246113.	2.5	8
10	Impact of hematocrit on point-of-care C-reactive protein-based tuberculosis screening among people living with HIV initiating antiretroviral therapy in Uganda. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115281.	1.8	2
11	Characterization of oral swab samples for diagnosis of pulmonary tuberculosis. <i>PLoS ONE</i> , 2021, 16, e0251422.	2.5	31
12	Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. <i>PLoS Medicine</i> , 2021, 18, e1003628.	8.4	31
13	Design and execution of a public randomization ceremony to enhance stakeholder engagement within a cluster randomized trial to improve tuberculosis diagnosis in Uganda. <i>Contemporary Clinical Trials Communications</i> , 2021, 22, 100707.	1.1	1
14	Diabetes prevention in the Caribbean using Lifestyle Intervention and Metformin Escalation (LIME): Protocol for a hybrid Type-1 effectiveness-implementation trial using a quasi-experimental study design. <i>Contemporary Clinical Trials Communications</i> , 2021, 22, 100750.	1.1	1
15	Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker perspectives. <i>Implementation Science Communications</i> , 2021, 2, 71.	2.2	6
16	Toward Comprehensive Plasma Proteomics by Orthogonal Protease Digestion. <i>Journal of Proteome Research</i> , 2021, 20, 4031-4040.	3.7	11
17	Where will it end? Pathways to care and catastrophic costs following negative TB evaluation in Uganda. <i>PLoS ONE</i> , 2021, 16, e0253927.	2.5	4
18	Field evaluation of a prototype tuberculosis lipoarabinomannan lateral flow assay on HIV-positive and HIV-negative patients. <i>PLoS ONE</i> , 2021, 16, e0254156.	2.5	3

#	ARTICLE	IF	CITATIONS
19	Barriers to the Use of Clinical Decision Support for the Evaluation of Pulmonary Embolism: Qualitative Interview Study. <i>JMIR Human Factors</i> , 2021, 8, e25046.	2.0	13
20	Validating novel diagnostic assays for tuberculosis in the context of existing tools. <i>The Lancet Global Health</i> , 2021, 9, e1209.	6.3	4
21	Patient Perspectives and Willingness to Accept Incentives for Tuberculosis Diagnostic Evaluation in Uganda. <i>Value in Health Regional Issues</i> , 2021, 25, 48-56.	1.2	6
22	Impact of shelter-in-place orders on TB case notifications and mortality in the Philippines during the COVID-19 pandemic. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2021, 25, 100282.	1.3	4
23	Completion of isoniazidâ€“rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectivenessâ€“implementation randomized trial. <i>PLoS Medicine</i> , 2021, 18, e1003875.	8.4	6
24	Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis. <i>New England Journal of Medicine</i> , 2021, 385, 2441-2450.	27.0	13
25	Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2020, 18, 100136.	1.3	12
26	Patient and health system factors associated with pretreatment loss to follow up among patients diagnosed with tuberculosis using XpertA® MTB/RIF testing in Uganda. <i>BMC Public Health</i> , 2020, 20, 1855.	2.9	4
27	Costs incurred by patients with drug-susceptible pulmonary tuberculosis in semi-urban and rural settings of Western India. <i>Infectious Diseases of Poverty</i> , 2020, 9, 144.	3.7	10
28	Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. <i>Implementation Science</i> , 2020, 15, 65.	6.9	8
29	Lipoarabinomannan antigenic epitope differences in tuberculosis disease subtypes. <i>Scientific Reports</i> , 2020, 10, 13944.	3.3	8
30	Predictors of Quality Improvement in Pediatric Asthma Care. <i>Hospital Pediatrics</i> , 2020, 10, 1114-1119.	1.3	1
31	Evaluation of multi-antigen serological screening for active tuberculosis among people living with HIV. <i>PLoS ONE</i> , 2020, 15, e0234130.	2.5	8
32	Challenges with scale-up of GeneXpert MTB/RIFÂ® in Uganda: a health systems perspective. <i>BMC Health Services Research</i> , 2020, 20, 162.	2.2	23
33	The University of California San Francisco (UCSF) Training Program in Implementation Science: Program Experiences and Outcomes. <i>Frontiers in Public Health</i> , 2020, 8, 94.	2.7	7
34	Study protocol: a cluster randomized trial to evaluate the effectiveness and implementation of onsite GeneXpert testing at community health centers in Uganda (XPEL-TB). <i>Implementation Science</i> , 2020, 15, 24.	6.9	14
35	Variation in tuberculosis treatment outcomes and treatment supervision practices in Uganda. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2020, 21, 100184.	1.3	6
36	Study protocol and implementation details for a pragmatic, stepped-wedge cluster randomised trial of a digital adherence technology to facilitate tuberculosis treatment completion. <i>BMJ Open</i> , 2020, 10, e039895.	1.9	11

#	ARTICLE	IF	CITATIONS
37	Estimating the effect of pretreatment loss to follow up on TB associated mortality at public health facilities in Uganda. <i>PLoS ONE</i> , 2020, 15, e0241611.	2.5	11
38	Iterative Adaptation of a Tuberculosis Digital Medication Adherence Technology to Meet User Needs: Qualitative Study of Patients and Health Care Providers Using Human-Centered Design Methods. <i>JMIR Formative Research</i> , 2020, 4, e19270.	1.4	13
39	Feasibility of a short message service (SMS) intervention to deliver tuberculosis testing results in peri-urban and rural Uganda. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2019, 16, 100110.	1.3	15
40	Guidance for Studies Evaluating the Accuracy of Tuberculosis Triage Tests. <i>Journal of Infectious Diseases</i> , 2019, 220, S116-S125.	4.0	33
41	Improving the cascade of global tuberculosis care: moving from the "what" to the "how" of quality improvement. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e437-e443.	9.1	22
42	Diagnostic accuracy of TB-LAMP for pulmonary tuberculosis: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2019, 19, 268.	2.9	48
43	Quality of care for patients evaluated for tuberculosis in the context of Xpert MTB/RIF scale-up. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2019, 15, 100099.	1.3	6
44	Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening. <i>Diagnostics</i> , 2019, 9, 56.	2.6	2
45	Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015. <i>BMC Public Health</i> , 2019, 19, 446.	2.9	21
46	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. <i>Lancet</i> , The, 2019, 393, 1331-1384.	13.7	257
47	Ultrasensitive detection of lipoarabinomannan with plasmonic grating biosensors in clinical samples of HIV negative patients with tuberculosis. <i>PLoS ONE</i> , 2019, 14, e0214161.	2.5	24
48	Outlook for tuberculosis elimination in California: An individual-based stochastic model. <i>PLoS ONE</i> , 2019, 14, e0214532.	2.5	15
49	Seasonality of childhood tuberculosis cases in Kampala, Uganda, 2010-2015. <i>PLoS ONE</i> , 2019, 14, e0214555.	2.5	9
50	Investigation of Preanalytical Variables Impacting Pathogen Cell-Free DNA in Blood and Urine. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	33
51	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e93-e142.	5.6	282
52	Point-of-care C-reactive protein and risk of early mortality among adults initiating antiretroviral therapy. <i>Aids</i> , 2019, 33, 895-902.	2.2	9
53	Brief Report: Yield and Efficiency of Intensified Tuberculosis Case-Finding Algorithms in 2 High-Risk HIV Subgroups in Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 416-420.	2.1	6
54	Yield and Efficiency of Novel Intensified Tuberculosis Case-Finding Algorithms for People Living with HIV. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 643-650.	5.6	36

#	ARTICLE	IF	CITATIONS
55	A Novel, 5-Transcript, Whole-blood Gene-expression Signature for Tuberculosis Screening Among People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2019, 69, 77-83.	5.8	20
56	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 564-571.	5.6	20
57	Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A systematic review and analysis of trial design considerations. <i>Wellcome Open Research</i> , 2019, 4, 173.	1.8	2
58	Variation in the observed effect of Xpert MTB/RIF testing for tuberculosis on mortality: A systematic review and analysis of trial design considerations. <i>Wellcome Open Research</i> , 2019, 4, 173.	1.8	2
59	Selecting and Improving Quasi-Experimental Designs in Effectiveness and Implementation Research. <i>Annual Review of Public Health</i> , 2018, 39, 5-25.	17.4	187
60	Brief Report: “Give Me Some Time” Facilitators of and Barriers to Uptake of Home-Based HIV Testing During Household Contact Investigation for Tuberculosis in Kampala, Uganda. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 400-404.	2.1	10
61	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 265-275.	10.7	80
62	Whole-genome sequencing and single nucleotide polymorphisms in multidrug-resistant clinical isolates of <i>Mycobacterium tuberculosis</i> from the Philippines. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 15, 239-245.	2.2	6
63	Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV. <i>PLoS ONE</i> , 2018, 13, e0206119.	2.5	11
64	Effectiveness-implementation of COPD case finding and self-management action plans in low- and middle-income countries: global excellence in COPD outcomes (GECO) study protocol. <i>Trials</i> , 2018, 19, 571.	1.6	26
65	Association of Rapid Molecular Testing With Duration of Respiratory Isolation for Patients With Possible Tuberculosis in a US Hospital. <i>JAMA Internal Medicine</i> , 2018, 178, 1380.	5.1	22
66	Identifying barriers to and facilitators of tuberculosis contact investigation in Kampala, Uganda: a behavioral approach. <i>Implementation Science</i> , 2017, 12, 33.	6.9	77
67	Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study. <i>Lancet Infectious Diseases</i> , 2017, 17, 1285-1292.	9.1	96
68	Unusual Radiographic Presentation of <i>Pneumocystis</i> Pneumonia in a Patient with AIDS. <i>Case Reports in Infectious Diseases</i> , 2017, 2017, 1-6.	0.5	10
69	Evaluation of antibody responses to panels of <i>M. tuberculosis</i> antigens as a screening tool for active tuberculosis in Uganda. <i>PLoS ONE</i> , 2017, 12, e0180122.	2.5	27
70	Sputum quality and diagnostic performance of GeneXpert MTB/RIF among smear-negative adults with presumed tuberculosis in Uganda. <i>PLoS ONE</i> , 2017, 12, e0180572.	2.5	37
71	Cost-effectiveness of triage testing for facility-based systematic screening of tuberculosis among Ugandan adults. <i>BMJ Global Health</i> , 2016, 1, e000064.	4.7	7
72	Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays. <i>BMC Public Health</i> , 2016, 16, 875.	2.9	11

#	ARTICLE	IF	CITATIONS
73	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 63, e147-e195.	5.8	916
74	Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model. <i>Scientific Reports</i> , 2016, 6, 30781.	3.3	27
75	Implementation of Xpert MTB/RIF in Uganda: Missed Opportunities to Improve Diagnosis of Tuberculosis. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw068.	0.9	42
76	Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifer Evaluation. <i>Journal of Clinical Microbiology</i> , 2016, 54, 274-282.	3.9	55
77	Strategies for implementing implementation science: a methodological overview. <i>Emergency Medicine Journal</i> , 2016, 33, 660-664.	1.0	92
78	Theory-Informed Interventions to Improve the Quality of Tuberculosis Evaluation at Ugandan Health Centers: A Quasi-Experimental Study. <i>PLoS ONE</i> , 2015, 10, e0132573.	2.5	24
79	In vitro immunomodulation for enhancing T cell-based diagnosis of <i>Mycobacterium tuberculosis</i> infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 41-45.	1.8	0
80	Health worker perspectives on barriers to delivery of routine tuberculosis diagnostic evaluation services in Uganda: a qualitative study to guide clinic-based interventions. <i>BMC Health Services Research</i> , 2015, 15, 10.	2.2	66
81	Transcriptional Adaptation of Drug-tolerant <i>Mycobacterium tuberculosis</i> During Treatment of Human Tuberculosis. <i>Journal of Infectious Diseases</i> , 2015, 212, 990-998.	4.0	82
82	Tobacco and tuberculosis: could we improve tuberculosis outcomes by helping patients to stop smoking?. <i>European Respiratory Journal</i> , 2015, 45, 583-585.	6.7	17
83	Changing Clinician Behavior When Less Is More. <i>JAMA Internal Medicine</i> , 2015, 175, 1921.	5.1	11
84	Investigating Barriers to Tuberculosis Evaluation in Uganda Using Geographic Information Systems. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 733-738.	1.4	12
85	A Clinical Predictor Score for 30-Day Mortality among HIV-Infected Adults Hospitalized with Pneumonia in Uganda. <i>PLoS ONE</i> , 2015, 10, e0126591.	2.5	23
86	Assessing the Quality of Tuberculosis Evaluation for Children with Prolonged Cough Presenting to Routine Community Health Care Settings in Rural Uganda. <i>PLoS ONE</i> , 2014, 9, e105935.	2.5	9
87	Impact of GeneXpert MTB/RIF Assay on Triage of Respiratory Isolation Rooms for Inpatients With Presumed Tuberculosis: A Hypothetical Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1353-1360.	5.8	40
88	The Lung Microbiome of Ugandan HIV-Infected Pneumonia Patients Is Compositionally and Functionally Distinct from That of San Franciscan Patients. <i>PLoS ONE</i> , 2014, 9, e95726.	2.5	53
89	A Transcriptional Signature for Active TB: Have We Found the Needle in the Haystack?. <i>PLoS Medicine</i> , 2013, 10, e1001539.	8.4	3
90	Bronchoalveolar Lavage Enzyme-Linked Immunospot for Diagnosis of Smear-Negative Tuberculosis in HIV-Infected Patients. <i>PLoS ONE</i> , 2012, 7, e39838.	2.5	17

#	ARTICLE	IF	CITATIONS
91	Impact of Xpert MTB/RIF Testing on Tuberculosis Management and Outcomes in Hospitalized Patients in Uganda. PLoS ONE, 2012, 7, e48599.	2.5	68
92	Interferon-Gamma Release Assays for the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Individuals: A Systematic Review and Meta-Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 230-238.	2.1	260
93	Integrated Strategies to Optimize Sputum Smear Microscopy. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 547-551.	5.6	42
94	Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. BMC Infectious Diseases, 2010, 10, 75.	2.9	33
95	Clinical Characteristics and Treatment Outcomes of Patients with Isoniazidâ€Mono-resistant Tuberculosis. Clinical Infectious Diseases, 2009, 48, 179-185.	5.8	98
96	Sensitivity of direct versus concentrated sputum smear microscopy in HIV-infected patients suspected of having pulmonary tuberculosis. BMC Infectious Diseases, 2009, 9, 53.	2.9	71
97	Poor Performance of Universal Sample Processing Method for Diagnosis of Pulmonary Tuberculosis by Smear Microscopy and Culture in Uganda. Journal of Clinical Microbiology, 2008, 46, 3325-3329.	3.9	23
98	Detailed Analysis of the Radiographic Presentation of Mycobacterium kansasii Lung Disease in Patients With HIV Infection. Chest, 2008, 133, 875-880.	0.8	27
99	Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. American Journal of Tropical Medicine and Hygiene, 2003, 68, 133-9.	1.4	88